Bal Pharma Limited

Bal Pharma Limited

Bal Pharma Limited has announced the disbursement of final dividend for FY 2025-26 and withholding of dividend for shareholders with incomplete KYC/bank details or invalid, blocked or closed bank accounts.

Bal Pharma Limited

Bal Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.

Bal Pharma Limited

Bal Pharma Limited has informed the Exchange regarding Change in Director(s) of the company, including re-appointment of Mr. Ravindra Kumar Kothari as a Director liable to retire by rotation and change in designation of Mr. Ravindra Kumar Kothari from Non-Executive Director to Whole-Time Director, and change in designation of Mr. Virupakshaya Himesh from Whole-Time Director to Non-Executive Director.

Bal Pharma Limited

Bal Pharma Limited has submitted the Exchange a copy of the Scrutinizer's report of the 39th Annual General Meeting held on September 24, 2026, and informed the Exchange regarding voting results.

Bal Pharma Limited

Bal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will remain closed from October 01, 2026, until 48 hours after the declaration of the Financial Results for the second quarter ending September 30, 2026.

Bal Pharma Limited

Bal Pharma Limited has held its 39th Annual General Meeting (AGM) on September 24, 2026, through video conferencing, where the company's financial statements for the year ended March 31, 2026, were adopted, and a dividend of Rs. 1.20 per equity share was declared.

Bal Pharma Limited

Bal Pharma Limited has responded to a query from the NSE regarding significant price movement in its shares, stating that it does not have any price-sensitive information and has made all necessary disclosures under SEBI regulations.

Bal Pharma Limited

The Bombay Stock Exchange has written to Bal Pharma Limited to inquire about the significant price movement in the company's stock, awaiting a response from the company.

Bal Pharma Limited

Bal Pharma Limited has informed the Exchange about Confirming the allotment of Convertible Warrants on Preferential basis to Mr. Shailesh Siroya, Promoter of the Company, at an issue price of ₹84/- (Rupees Eighty-Four only) per Warrant, aggregating to ₹8,40,00,000/-(Rupees Eight Crore Forty Lakh only).

Bal Pharma Limited

Bal Pharma Limited has announced the record date for the purpose of dividend payment as September 17, 2026, and communicated to shareholders regarding tax deduction at source (TDS) on final dividend payment.

Bal Pharma Limited

Bal Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026.

Bal Pharma Limited

Bal Pharma Limited has informed the Exchange about the fixation of its 39th Annual General Meeting (AGM) on September 24, 2026, and related dates for dividend payment and e-voting.

Bal Pharma Limited

Bal Pharma Limited has clarified the timeline for utilizing the net proceeds of its preferential issue, stating that it will be done within 18 months from the date of allotment.

Bal Pharma Limited

Bal Pharma Limited has published unaudited financial results for the quarter ended June 30, 2026, and a notice regarding the transfer of unclaimed dividend shares to the Investor Education and Protection Fund Authority.

Bal Pharma Limited

Bal Pharma Limited has announced the outcome of its board meeting, where it approved the unaudited financial results for the quarter ended June 30, 2026, and also approved changes in the designations of two directors, Mr. Ravindra Kumar Kothari and Mr. Virupakshaya Himesh. The company also approved an investment in a joint venture entity in the Philippines and the allotment of 10,00,000 warrants to a promoter on a preferential basis.

Bal Pharma Limited

Bal Pharma Limited has announced its financial results for the period ended June 30, 2026, and other matters from its board meeting. The company has approved the change in designation of two directors, made an investment in a joint venture entity in the Philippines, and allotted 10,00,000 warrants to a promoter at ₹84 per warrant.

Bal Pharma Limited

Bal Pharma Limited has informed the Exchange regarding the voting results of the Postal Ballot conducted through remote e-voting, where 99.96% of the total votes received have approved the issue of 10,00,000 Warrants to the Promoter of the Company on preferential basis.

Bal Pharma Limited

Bal Pharma Limited is providing an opportunity to shareholders to submit comments on the modifications made to the postal ballot notice, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bal Pharma Limited

Bal Pharma Limited replied to the Exchange's clarification on variations observed between XBRL and PDF financial submissions, confirming that the revised XBRL filings match the PDF financial results and that there has been no change in the financial results approved by the Board of Directors.

Bal Pharma Limited

Bal Pharma Limited has issued a corrigendum to its postal ballot notice dated July 9, 2026, regarding the proposed preferential issue of up to 10,00,000 convertible warrants to a promoter, with a revised issue price of ₹84 per warrant, including a premium of ₹74 per warrant.